EP1802615A1 — Phosphodiesterase 4 inhibitors
Assigned to Memory Pharmaceuticals Corp · Expires 2007-07-04 · 19y expired
What this patent protects
Selective PDE4 inhibition is achieved by novel compounds, e.g., 4-(substituted-phenyl)-2-pyrrolidinone compounds. The compounds of the present invention are of formula (I) wherein R1, R2, and R3 are as defined herein. The disclosure also relates to methods of preparing such compo…
USPTO Abstract
Selective PDE4 inhibition is achieved by novel compounds, e.g., 4-(substituted-phenyl)-2-pyrrolidinone compounds. The compounds of the present invention are of formula (I) wherein R1, R2, and R3 are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and use for treating cognition impairment memory impairment, psychosis, schizophrenia, depression, allergic or inflammatory disease, chronic obstructive pulmonary disease, neurodegeneration, stroke, Alzheimer’s disease, multiple sclerosis.
Drugs covered by this patent
- Briviact (BRIVARACETAM) · UCB
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.